StreetInsider.com News Articles

Form S-3 Jaguar Health, Inc.

Thu, 22 Oct 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20261022/27223463.html

Jaguar Health's crofelemer shows early benefit in third rare gut disorder

Wed, 21 Oct 2026 09:02:57 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary Napo Pharmaceuticals has been providing crofelemer powder for oral solution to an infant patient with congenital sodium diarrhea (CSD) caused by a GUCY2C gene mutation, a condition that results in intestinal failure (IF).

According to the company, liquid oral crofelemer therapy reduced the patient's daily parenteral support (PS) needs by approximately 15% within the first several weeks of treatment, with no significant clinical or laboratory abnormalities reported. Parenteral support, which can require up to 20 or more hours per day and up to seven days per week, is associated with serious and

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

Wed, 21 Oct 2026 09:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 21, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has been continuing to provide the company's novel crofelemer powder for oral solution for several weeks for the treatment of intestinal failure (IF) in an infant patient with GUCY2C mutation resulting in congenital sodium diarrhea (CSD). Liquid oral crofelemer therapy is well tolerated by this patient and has demonstrated reduced needs for daily and weekly parenteral support (PS) with no significant

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

Wed, 21 Oct 2026 09:00:00 -0400

Jaguar Health sets ex-dividend date for Series R preferred stock dividend

Wed, 14 Oct 2026 16:16:50 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) has announced that Nasdaq has set October 16, 2026, as the ex-dividend date for the company's previously announced special stock dividend, consisting of Series R Convertible Preferred Stock.

The dividend is payable on October 15, 2026, to holders of Jaguar common stock and certain outstanding warrants as of the record date of October 13, 2026.

Nasdaq has advised the company that its shares of common stock will trade with "due bills" from the record date of October 13, 2026, through the ex-dividend date of October 16, 2026. During this period, stockholders who sell their shares will also

Jaguar Health Provides Update Regarding Special Stock Dividend

Wed, 14 Oct 2026 16:15:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today provided an update in connection with the Company's previously announced special stock dividend (the "Special Stock Dividend"), which is payable on October 15, 2026, to holders of Jaguar common stock and certain outstanding warrants as of record on October 13, 2026, to announce that The Nasdaq Stock Market LLC ("Nasdaq") has indicated that the ex-dividend date for the Special Stock Dividend is October 16, 2026 (the

Jaguar Health Provides Update Regarding Special Stock Dividend

Wed, 14 Oct 2026 16:15:00 -0400

Jaguar Health unit presents crofelemer SBS-IF study data at ACG 2026

Wed, 14 Oct 2026 09:03:42 -0400

Napo Pharmaceuticals, a subsidiary of Jaguar Health, Inc. (NASDAQ: JAGX), presented preliminary results from an ongoing open-label pilot study of crofelemer powder for oral solution in adult patients with Type 1 short bowel syndrome with intestinal failure (SBS-IF) at the American College of Gastroenterology Annual Scientific Meeting on October 13, 2026.

The study enrolled adult SBS-IF patients on stable parenteral support, who received liquid crofelemer at 3 mg/kg/dose orally three times daily for 12 weeks. Four of a planned six participants have completed the protocol. Among results reported, two subjects showed decreased ostomy volume at 12 weeks by an average of

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar H

Wed, 14 Oct 2026 09:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the positive preliminary results presented on October 13, 2026 at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026) for the ongoing open-label pilot study of the company's crofelemer powder for oral solution in adult patients with Type 1 short bowel syndrome (T1SBS) with intestinal failure (SBS-IF). The abstract presented at ACG 2026, titled The Use of

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar H

Wed, 14 Oct 2026 09:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the positive preliminary results presented on October 13, 2026 at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026) for the ongoing open-label pilot study of the company's crofelemer powder for oral solution in adult patients with Type 1 short bowel syndrome (T1SBS) with intestinal failure (SBS-IF). The abstract presented at ACG 2026, titled The Use of

Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend

Tue, 13 Oct 2026 09:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today issued a reminder that today, October 13, 2026, is the Record Date for the Company's special stock dividend (the "Special Stock Dividend"). As announced, Jaguar's Board of Directors declared a Special Stock Dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend consists of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").
The

Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend

Tue, 13 Oct 2026 09:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today issued a reminder that today, October 13, 2026, is the Record Date for the Company's special stock dividend (the "Special Stock Dividend"). As announced, Jaguar's Board of Directors declared a Special Stock Dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend consists of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").
The

Form DEF 14A Jaguar Health, Inc. For: Nov 06

Thu, 08 Oct 2026 16:26:00 -0400
si-local-file:///var/storage/secattach/20261008/27167277.html

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

Tue, 06 Oct 2026 09:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a sponsor of the 2nd Best of Elite Ped-GI meeting in Abu Dhabi in the United Arab Emirates and is also sponsoring a panel discussion titled Intestinal Barrier Beyond Total Parenteral Nutrition (TPN) on October 30, 2026 at the meeting. Participants in the panel discussion include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, and Pravin Chaturvedi, PhD, Napo's and Jaguar's

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

Tue, 06 Oct 2026 09:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a sponsor of the 2nd Best of Elite Ped-GI meeting in Abu Dhabi in the United Arab Emirates and is also sponsoring a panel discussion titled Intestinal Barrier Beyond Total Parenteral Nutrition (TPN) on October 30, 2026 at the meeting. Participants in the panel discussion include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, and Pravin Chaturvedi, PhD, Napo's and Jaguar's

Form 8-K Jaguar Health, Inc. For: Sep 30

Mon, 05 Oct 2026 08:45:00 -0400
si-local-file:///var/storage/secattach/20261005/27146332.html

Jaguar Health Announces a Special Stock Dividend

Fri, 02 Oct 2026 20:35:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Series R Convertible Preferred Stock (the "Preferred Stock"). The CUSIP number for the Preferred Stock is 47010C847.
Only persons who own shares of the Company's voting common

Jaguar Health Announces a Special Stock Dividend

Fri, 02 Oct 2026 20:35:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Series R Convertible Preferred Stock (the "Preferred Stock"). The CUSIP number for the Preferred Stock is 47010C847.
Only persons who own shares of the Company's voting common

Form PRER14A Jaguar Health, Inc.

Tue, 29 Sep 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260929/27122697.html

Napo Pharmaceuticals crofelemer study accepted for ACG 2026 meeting

Tue, 29 Sep 2026 06:03:39 -0400

Napo Pharmaceuticals, a subsidiary of Jaguar Health, Inc. (NASDAQ: JAGX), announced that an abstract on preliminary results from an ongoing open-label study of crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) has been accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026), scheduled for October 9-14, 2026, in Nashville, Tennessee.
Napo is also conducting a separate multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in adult Type 1 SBS patients without colon-in-continuity. Results from that trial are expected in the first half of 2027.
In June 2026, data from

Napo Pharmaceuticals crofelemer study accepted for ACG 2026 meeting

Tue, 29 Sep 2026 06:03:39 -0400

Napo Pharmaceuticals, a subsidiary of Jaguar Health, Inc. (NASDAQ: JAGX), announced that an abstract on preliminary results from an ongoing open-label study of crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) has been accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026), scheduled for October 9-14, 2026, in Nashville, Tennessee.
Napo is also conducting a separate multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in adult Type 1 SBS patients without colon-in-continuity. Results from that trial are expected in the first half of 2027.
In June 2026, data from

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of

Tue, 29 Sep 2026 04:30:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026). ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.
Napo is conducting a multicenter, randomized double-blind

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of

Tue, 29 Sep 2026 04:30:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026). ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.
Napo is conducting a multicenter, randomized double-blind

Form 8-K Jaguar Health, Inc. For: Sep 25

Mon, 28 Sep 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260928/27109892.html

Form 8-K Jaguar Health, Inc. For: Sep 23

Fri, 25 Sep 2026 06:00:00 -0400
si-local-file:///var/storage/secattach/20260925/27103660.html